Hodgkin Lymphoma Treatment Market To Reach $10.1 Billion by 2035

Hodgkin lymphoma treatment market is projected to grow from $5.2 billion in 2025 to $10.1 billion by 2035, registering a CAGR of 6.8% during the forecast period. Market growth is primarily driven by the rising global cancer burden, the increasing adoption of immunotherapy, and advancements in targeted oncology drugs. A key macro driver supporting market expansion is the rising incidence of cancer worldwide. According to the World Health Organization report published in February 2024, cancer accounted for nearly 10 million deaths globally in 2022, making it one of the leading causes of mortality.

Browse the full report description of “Hodgkin Lymphoma Treatment Market Size, Share & Trends Analysis Report, By Treatment Modality (Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy, Others), By Drug Class (Cytotoxic Drugs, ADC, Immune Checkpoint Inhibitors, Corticosteroids), By Route of Administration (IV, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/hodgkin-lymphoma-treatment-market

Among drug classes, immune checkpoint inhibitors are witnessing the fastest growth due to their superior clinical outcomes. The premium pricing and expanding indications are significantly contributing to revenue growth. From a regional perspective, North America dominates the market due to strong healthcare infrastructure, high adoption of advanced therapies, and favourable reimbursement policies. However, Asia-Pacific is expected to witness the fastest growth, supported by rising healthcare expenditure and increasing cancer awareness initiatives led by governments and global health organizations.

Competitive Landscape

Key companies operating in the global Hodgkin lymphoma treatment market include Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer, Takeda Pharmaceutical Company Limited, and others. The market is highly competitive, driven by continuous advancements in immunotherapy and targeted treatments. Additionally, increasing investment in clinical trials and pursuing strategic collaborations to strengthen their global presence.

Recent Developments

• In March 2026, Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration approved Opdivo (nivolumab) in combination with chemotherapy (AVD regimen) for the treatment of adult and pediatric patients aged 12 years and older with previously untreated Stage III or IV classical Hodgkin lymphoma. This approval establishes the first immunotherapy-based combination in frontline treatment and significantly improves progression-free survival outcomes.

• In January 2025, Takeda Pharmaceutical Company Limited announced that the European Commission approved ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of patients with previously untreated advanced-stage classical Hodgkin lymphoma. The approval expands the availability of antibody-drug conjugate–based frontline therapy in Europe and strengthens Takeda’s position in the lymphoma treatment market.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• By Treatment Modality
• By Drug Class
• By Route of Administration
• By Distribution Channel
• Regions Covered
• North America
• Europe
• Asia- Pacific
• Rest of the World
• Competitive Landscape – Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer, Takeda Pharmaceutical Company Limited, and others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Hodgkin Lymphoma Treatment Market Report Segment

By Treatment Modality

• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Targeted Therapy
• Others

By Drug Class

• Cytotoxic Drugs (Chemotherapy)
• Antibody-Drug Conjugates (ADC)
• Immune Checkpoint Inhibitors
• Corticosteroids (supportive, minor share)

By Route of Administration

• Intravenous (IV)
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Hodgkin Lymphoma Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hodgkin-lymphoma-treatment-market